China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively.

Illumina (NASDAQ:ILMN – Get Free Report) was downgraded by investment analysts at Barclays from an “equal weight” rating to ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...